Heberden Oration, 1988. Exploring immune pathways in rheumatoid arthritis

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.

Annals of the rheumatic diseases·2008

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

Arthritis and rheumatism·2006

Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis.

Arthritis and rheumatism·2005

Anti-TNF therapy: where have we got to in 2005?

Journal of autoimmunity·2005

The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?

Annals of the rheumatic diseases·2005

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.

Arthritis and rheumatism·2005

Hypothyroid myopathy as a complication of interferon alpha therapy for chronic hepatitis C virus infection.

British journal of rheumatology·1999

Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients.

British journal of rheumatology·1999

Circulating interleukin-16 in systemic lupus erythematosus.

British journal of rheumatology·1999

Antibodies to Klebsiella pneumoniae lipopolysaccharide in patients with ankylosing spondylitis.

British journal of rheumatology·1999

Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years.

British journal of rheumatology·1999

A study of the frequency of pericardial and pleural effusions in scleroderma.

British journal of rheumatology·1999

Allopurinol-Induced Leukocytoclastic Vasculitis With Systemic Inflammatory Response: A Case Report From Azerbaijan.

Cureus·2026

From inflammation to rupture: advances in the pathogenesis of pseudoaneurysm formation in Vascular Behçet's Disease.

Frontiers in immunology·2026

TREM2 as a central hub of neuroimmune-metabolic crosstalk in central nervous system disorders: from microglial biology to therapeutic targeting.

Frontiers in immunology·2026

The immune microenvironment and population heterogeneity in myasthenia gravis: implications for precision therapeutics.

Frontiers in immunology·2026

Autoimmunity: Molecular Mechanisms, Biomarkers, and Therapeutic Opportunities.

MedComm·2026

Molecular basis of post-translational neoantigen generation in rheumatoid arthritis: breaking immunological tolerance and implications for targeted therapy.

Frontiers in immunology·2026

Related Experiment Videos

Heberden Oration, 1988. Exploring immune pathways in rheumatoid arthritis

Related Concept Videos

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis.

Anti-TNF therapy: where have we got to in 2005?

The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.

Hypothyroid myopathy as a complication of interferon alpha therapy for chronic hepatitis C virus infection.

Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients.

Circulating interleukin-16 in systemic lupus erythematosus.

Antibodies to Klebsiella pneumoniae lipopolysaccharide in patients with ankylosing spondylitis.

Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years.

A study of the frequency of pericardial and pleural effusions in scleroderma.

Allopurinol-Induced Leukocytoclastic Vasculitis With Systemic Inflammatory Response: A Case Report From Azerbaijan.

From inflammation to rupture: advances in the pathogenesis of pseudoaneurysm formation in Vascular Behçet's Disease.

TREM2 as a central hub of neuroimmune-metabolic crosstalk in central nervous system disorders: from microglial biology to therapeutic targeting.

The immune microenvironment and population heterogeneity in myasthenia gravis: implications for precision therapeutics.

Autoimmunity: Molecular Mechanisms, Biomarkers, and Therapeutic Opportunities.

Molecular basis of post-translational neoantigen generation in rheumatoid arthritis: breaking immunological tolerance and implications for targeted therapy.

Related Experiment Videos

Heberden Oration, 1988. Exploring immune pathways in rheumatoid arthritis

Related Concept Videos

Related Articles